Almiral made a net profit of €20.4 million In the first quarter of the year, which is down 31.5% compared to the same period in 2021, as reported by the company, which specified that its normalized net income stood at 20.5 million euros, half of what was registered a year earlier. Was.
net sales of biopharmaceuticalexcluding the contribution of astraZeneca You covis pharmareached EUR 218.8 million between January and March of this year, an increase of 1.6% year-on-year and “strong performance”. dermatology profession in Europe”, where sales increased 31% year-on-year.
Almirall’s gross operating profit (Ebitda) for the first quarter totaled €59.6 million. year-on-year decline of 19.7% including a net positive effect of the amount of EUR 9 million from other income related to the agreement of astraZeneca You covis pharma,
other then astraZeneca You covis pharmaAs of March, Almirall’s EBITDA stood at EUR 68 million, down 26% compared to the first quarter of 2021.
Although biopharmaceutical It specified that this result is “in line with expected growth”, as a positive impact of EUR 16 million was recorded in non-recurring items in the first quarter of 2021.
After “strong results” in the first quarter, the group maintains its 2022 target of mid-single-digit growth in net sales excluding AstraZeneca and Covis Pharma, and a EBITDA Total between 190 and 210 million euros.
As announced by the company last February, Charles Gallardo After the decision of his father, on 6 May, assumed the chairmanship of the board of directors of Almirall, Jorge Gallardo Ballartto leave the office.
Carlos Gallardo has extensive international experience in the field health, He had early in his pharmaceutical career New York in multinational pfizer Prior to joining Almirall, where he held various positions for almost 10 years, rose to executive positions.
Since leaving the company as CEO of United Kingdom I Ireland In 2013, he was a member of the Almirall Board of Directors. Besides, he. is the founder and CEO of CG Health Ventureswho invests in and builds digital health companies and is a member of the board of directors of several medical technology and digital health startups.
The company has highlighted that Gallardo’s international experience in the pharmaceutical industry as well as the digital health sector will “contribute to Almirol’s growth and strengthening its position as a leader. dermatology,
“I am delighted to assume the role of Chairman of the Almirol Board of Directors and bring consistency to the company’s clear focus and strategy. We have one of the strongest late-stage pipelines medical dermatology And I am confident that, with the solid management team we have in place, we will ensure Almirol’s leadership position in this area”, Gallardo underlined.
We have one of the strongest late-stage pipelines in medical dermatology
The biopharmaceutical company’s new chairman also highlighted that the company’s “solid operating performance” in the first quarter puts it on track to achieve it. objectives till 2022.
“During the quarter we saw a strong boost from Almirol’s growth engine and core business, driven by recently launched products and the company’s European portfolio. dermatology (…), Gallardo pointed out, that Almirol continues to seek “opportunistic inorganic growth”, taking advantage of its “solid balance sheet” and its flexible capital structure.